Promis Neurosciences (PMN) Projected to Post Quarterly Earnings on Monday

Key Points

• Promis Neurosciences is expected to report Q1 2026 results before the market opens on Monday, May 11, with analysts forecasting an EPS loss of ($1.06); an earnings call is scheduled for May 13 at 9:30 AM ET.
• The stock recently traded at $11.19 (50‑day MA $15.84, 200‑day MA $12.04), has a 12‑month range of $6.27–$39.75 and a market capitalization of roughly $100.35 million.
• Investor sentiment is mixed—MarketBeat shows an average "Moderate Buy" and a $42.67 price target despite recent downgrades—while insiders have been buying heavily (over 709,000 shares in the last 90 days) and institutional ownership is about 50%, including a notable stake increase by Citadel Advisors.

Promis Neurosciences (NASDAQ:PMN - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Monday, May 11th. Analysts expect the company to announce earnings of ($1.06) per share for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Wednesday, May 13, 2026 at 9:30 AM ET.

Promis Neurosciences Stock Performance

NASDAQ PMN traded up $0.18 on Monday, hitting $11.19. 11,010 shares of the stock traded hands, compared to its average volume of 137,727. The business's fifty day moving average is $15.84 and its two-hundred day moving average is $12.04. Promis Neurosciences has a 12 month low of $6.27 and a 12 month high of $39.75. The firm has a market capitalization of $100.35 million, a price-to-earnings ratio of -0.59 and a beta of -0.20.

Wall Street Analyst Weigh In

PMN has been the subject of several research reports. Guggenheim reduced their price objective on Promis Neurosciences from $125.00 to $35.00 and set a "buy" rating for the company in a report on Friday, February 6th. Wall Street Zen downgraded Promis Neurosciences to a "strong sell" rating in a research report on Saturday, February 14th. Finally, Weiss Ratings restated a "sell (e+)" rating on shares of Promis Neurosciences in a research report on Thursday, January 22nd. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $42.67.

Insider Transactions at Promis Neurosciences

In other news, insider Johanne Kaplan purchased 1,629 shares of the stock in a transaction on Thursday, February 19th. The shares were acquired at an average price of $15.35 per share, for a total transaction of $25,005.15. Following the completion of the transaction, the insider directly owned 3,941 shares of the company's stock, valued at approximately $60,494.35. This trade represents a 70.46% increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. Also, Director Patrick D. Kirwin purchased 4,000 shares of the stock in a transaction on Wednesday, April 22nd. The shares were purchased at an average price of $11.33 per share, for a total transaction of $45,320.00. Following the transaction, the director directly owned 4,653 shares of the company's stock, valued at approximately $52,718.49. This represents a 612.56% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Over the last ninety days, insiders have acquired 709,370 shares of company stock worth $8,640,843. Company insiders own 1.50% of the company's stock.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Promis Neurosciences stock. Citadel Advisors LLC lifted its stake in Promis Neurosciences (NASDAQ:PMN - Free Report) by 168.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 170,079 shares of the company's stock after buying an additional 106,650 shares during the period. Citadel Advisors LLC owned approximately 0.32% of Promis Neurosciences worth $72,000 as of its most recent SEC filing. Institutional investors and hedge funds own 50.13% of the company's stock.

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company's research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer's disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.